Trials / Recruiting
RecruitingNCT07110584
Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors
A Phase 1/2, Multi-Center, Open-Label Clinical Study Evaluating MDX2004 In Participants With Advanced Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 235 (estimated)
- Sponsor
- ModeX Therapeutics, An OPKO Health Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MDX2004 | MDX2004 intravenous infusion |
Timeline
- Start date
- 2025-10-01
- Primary completion
- 2031-06-30
- Completion
- 2031-06-30
- First posted
- 2025-08-07
- Last updated
- 2026-03-05
Locations
6 sites across 2 countries: Australia, Israel
Source: ClinicalTrials.gov record NCT07110584. Inclusion in this directory is not an endorsement.